Knee Pain in Younger Adults

Cartilage cushions the joints, and while wear is often associated with ageing, it is increasingly common in younger, active adults — particularly after sports injuries or repetitive loading. For this group, protecting and preserving the joint matters considerably: the aim is to reduce symptoms, slow progression, and keep surgery off the table for as long as possible. Many younger patients are therefore interested in non-surgical options before committing to any operative pathway.

What Is the ChondroFiller Injection?

ChondroFiller is a CE-marked Class III medical device — a type I collagen hydrogel scaffold made by Meidrix Biomedicals in Germany and imported into the UK under prescription. In its injection form, it is delivered as an ultrasound-guided outpatient procedure: a fine needle introduces the liquid scaffold directly into the affected joint under imaging guidance, with no incision and no general anaesthetic.

Once inside the joint, the collagen gel self-sets in approximately three to five minutes, forming a porous three-dimensional matrix. This scaffold acts as a biological framework, recruiting the patient's own progenitor cells to migrate in and remodel the material towards cartilage tissue over the following months. It is acellular — it contains no donor cells — and is gradually resorbed as new tissue forms.

It is best understood as a supportive, joint-preserving intervention: it may ease symptoms and provide a regenerative scaffold over worn surfaces, but it is not a cure and does not reverse established arthritis. Benefits vary between individuals, and outcomes cannot be guaranteed.

Who May Be Suitable?

The ChondroFiller injection may suit younger, active adults with localised focal cartilage wear affecting the knee, where arthritis is early or limited. Because it is non-surgical, it is well tolerated by people who need to return to activity promptly and prefer to avoid operative recovery.

It is not appropriate for everyone. Joints with significant malalignment, advanced arthritis, or large load-bearing defects are generally not suitable for the injection pathway. A consultation with clinical examination and appropriate imaging — typically MRI — is needed to confirm whether the injection is the right approach for a given patient and defect.

ChondroFiller Injection vs Liquid Cartilage: Understanding the Difference

The ChondroFiller injection and the Liquid Cartilage procedure both use ChondroFiller as the scaffold material, but they are distinct in nature and indication.

The ChondroFiller injection is non-surgical: it is an outpatient, ultrasound-guided injection suitable for accessible defects, smaller lesions, and patients for whom surgery is not indicated or preferred.

The Liquid Cartilage procedure — formally the Lee Liquid Cartilage Protocol — is Professor Paul Y. F. Lee's keyhole surgical technique. Performed arthroscopically under anaesthetic, it combines the ChondroFiller scaffold with biological adjuncts including platelet-rich fibrin, platelet-rich plasma, and tranexamic acid, with the option to add the patient's own mesenchymal stem cells from bone-marrow aspirate concentrate or micro-fragmented fat where clinical need warrants it. The surgical approach is designed for larger or more complex load-bearing defects in the knee, hip, shoulder, and ankle, where precise arthroscopic preparation, a dry operating field, and peri-operative biological optimisation are needed to achieve durable repair.

For younger adults, the right pathway depends on the size and location of the defect, the degree of cartilage loss, joint alignment, and activity demands. Some patients are well served by the injection; others will benefit more from the surgical protocol. A specialist assessment determines which is appropriate.

What to Expect During and After the Injection

Treatment begins with a detailed consultation, clinical examination, and review of relevant imaging. If the ChondroFiller injection is confirmed as appropriate, the procedure itself is minimally invasive: no incision is made, and patients are not admitted overnight. Ultrasound guidance ensures accurate delivery into the defect.

Because it is non-surgical, recovery is straightforward for most people. Return to normal daily activity is usually prompt, and physiotherapy is recommended where helpful to restore strength, movement, and loading patterns.

Evidence and Realistic Expectations

ChondroFiller carries CE Class III certification, which reflects a rigorous regulatory assessment of its safety and performance as a medical device. Published clinical data — including a study by Corain and colleagues (2023, Cartilage) in the trapeziometacarpal joint — demonstrate its use across different joints and patient groups. For knee applications, evidence from published series suggests functional improvement over a twelve to thirty-six month period, though the magnitude of benefit varies with patient and defect characteristics.

Patients should approach treatment with realistic expectations. ChondroFiller is a regenerative scaffold, not a guaranteed solution; it supports the biological conditions for repair but cannot predictably restore cartilage in every case. Its resorbable nature means it is gradually replaced by the body's own tissue, which avoids the long-term risks associated with permanent synthetic fillers.

Next Steps

For younger adults with knee pain from focal cartilage wear, the ChondroFiller injection offers a non-surgical pathway that may ease symptoms and support the joint without an operative recovery. Whether it is the right option — or whether the Liquid Cartilage surgical procedure would be more appropriate — depends on individual anatomy, defect characteristics, and clinical goals.

The London Cartilage Clinic, based on Harley Street, offers specialist assessment for both pathways. A consultation with Professor Paul Lee includes a thorough examination and imaging review, with advice tailored to each patient's joint, activity level, and realistic aims.

References

Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.